| Name | Title | Contact Details |
|---|---|---|
Luke Gordon |
Vice President of Network Development | Profile |
InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.
Boehringer Laboratories, LLC. is a family owned American medical technology company with headquarters in Phoenixville, Pennsylvania.
At PharmScript, we are healthcare professionals first. Together, we believe in the power of helping our clients deliver true patient-centered care.
Amgenix International is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.